Definium offers asymmetric CNS biotech upside built on best-in-class Phase 3 psychedelic psychiatry data, but its valuation remains tightly tied to upcoming GAD readouts, FDA/DEA decisions, and real-world clinic adoption.
Overview
Definium Therapeutics is a pre-revenue, late-stage CNS biotech developing psychedelic-derived psychiatric medicines, led by DT120 ODT, a sublingual lysergide tablet in Phase 3 trials for GAD and MDD, with PTSD planned. The company targets large underserved treatment-resistant psychiatric populations through a supervised clinical model designed for rapid symptom relief, durable efficacy, and scalable administration without mandatory psychotherapy. Positive MDD data and GAD Breakthrough Therapy Designation make DT120 the central value driver, while DT402 offers earlier-stage optionality in autism spectrum disorder.